全文获取类型
收费全文 | 10701篇 |
免费 | 454篇 |
国内免费 | 150篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 173篇 |
妇产科学 | 89篇 |
基础医学 | 1144篇 |
口腔科学 | 290篇 |
临床医学 | 650篇 |
内科学 | 2986篇 |
皮肤病学 | 154篇 |
神经病学 | 685篇 |
特种医学 | 422篇 |
外科学 | 2325篇 |
综合类 | 46篇 |
预防医学 | 217篇 |
眼科学 | 147篇 |
药学 | 589篇 |
中国医学 | 15篇 |
肿瘤学 | 1297篇 |
出版年
2024年 | 7篇 |
2023年 | 89篇 |
2022年 | 159篇 |
2021年 | 300篇 |
2020年 | 179篇 |
2019年 | 199篇 |
2018年 | 256篇 |
2017年 | 203篇 |
2016年 | 253篇 |
2015年 | 263篇 |
2014年 | 374篇 |
2013年 | 442篇 |
2012年 | 686篇 |
2011年 | 764篇 |
2010年 | 405篇 |
2009年 | 353篇 |
2008年 | 637篇 |
2007年 | 671篇 |
2006年 | 687篇 |
2005年 | 770篇 |
2004年 | 731篇 |
2003年 | 674篇 |
2002年 | 654篇 |
2001年 | 134篇 |
2000年 | 104篇 |
1999年 | 150篇 |
1998年 | 177篇 |
1997年 | 132篇 |
1996年 | 132篇 |
1995年 | 89篇 |
1994年 | 79篇 |
1993年 | 75篇 |
1992年 | 55篇 |
1991年 | 59篇 |
1990年 | 46篇 |
1989年 | 49篇 |
1988年 | 44篇 |
1987年 | 37篇 |
1986年 | 30篇 |
1985年 | 26篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 8篇 |
1981年 | 12篇 |
1980年 | 7篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 6篇 |
1975年 | 7篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
Nishiguchi S Shiomi S Sasaki N Iwata Y Tanaka H Kubo S Hirohashi K Ochi H 《Annals of nuclear medicine》2000,14(5):383-386
A 39-year-old woman with acute cholecystitis and gallstones underwent laparoscopic cholecystectomy. She suffered from recurrent episodes of cholangitis due to injury of the major bile ducts during laparoscopic cholecystectomy. Hepatobiliary scintigraphy with Tc-99m Sn-N-pyridoxyl-5-methyltryptophan was performed. Although normal bile excretion was found from the left hepatic duct to the percutaneous transhepatic biliary drainage (PTBD) tube, excretion from the right hepatic lobe was prolonged. Scintigraphy with Tc-99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin demonstrated atrophy of the right hepatic lobe and enlargement of the left hepatic lobe. Cholangiography via the PTBD tube revealed complete obstruction of the left hepatico-jejunal anastomosis and could not enhance the right intrahepatic bile duct. A right hepatic lobectomy was performed because of the atrophy, glissonitis and the absence of an appropriate bile duct for reconstruction. Postoperatively she was active and exhibited no evidence of recurrent cholangitis. 相似文献
112.
Tomohiro Komatsu Makoto Ayaori Harumi Uto-Kondo Katsumi Hayashi Katsumi Tamura Hiroki Sato Makoto Sasaki Takafumi Nishida Shunichi Takiguchi Emi Yakushiji Kazuhiro Nakaya Katsunori Ikewaki 《Journal of atherosclerosis and thrombosis》2022,29(5):775
Aims: Inflammation is involved in various processes of atherosclerosis development. Serum C-reactive protein (CRP) levels, a predictor for cardiovascular risk, are reportedly reduced by statins. However, several studies have demonstrated that CRP is a bystander during atherogenesis. While S100A12 has been focused on as an inflammatory molecule, it remains unclear whether statins affect circulating S100A12 levels. Here, we investigated whether atorvastatin treatment affected S100A12 and which biomarkers were correlated with changes in arterial inflammation. Methods: We performed a prospective, randomized open-labeled trial on whether atorvastatin affected arterial (carotid and thoracic aorta) inflammation using18fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and inflammatory markers. Thirty-one statin-naïve patients with carotid atherosclerotic plaques were randomized to either a group receiving dietary management (n=15) or one receiving atorvastatin (10mg/day,n=16) for 12weeks.18F-FDG-PET/CT and flow-mediated vasodilation (FMD) were performed, the latter to evaluate endothelial function. Results: Atorvastatin, but not the diet-only treatment, significantly reduced LDL-cholesterol (LDL-C, -43%), serum CRP (-37%) and S100A12 levels (-28%) and improved FMD (+38%).18F-FDG-PET/CT demonstrated that atorvastatin, but not the diet-only treatment, significantly reduced accumulation of18F-FDG in the carotid artery and thoracic aorta. A multivariate analysis revealed that reduction in CRP, S100A12, LDL-C, oxidized-LDL, and increase in FMD were significantly associated with reduced arterial inflammation in the thoracic aorta, but not in the carotid artery. Conclusions: Atorvastatin treatment reduced S100A12/CRP levels, and the changes in these circulating markers mirrored the improvement in arterial inflammation. Our observations suggest that S100A12 may be an emerging therapeutic target for atherosclerosis. 相似文献
113.
T‐cell‐rich HLA‐haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy 下载免费PDF全文
Hideki Sano Kazuhiro Mochizuki Mitsuko Akaihata Shogo Kobayashi Hitoshi Ohto Atsushi Kikuta 《Pediatric blood & cancer》2017,64(3)
Intensive chemotherapy with tyrosine kinase inhibitor (TKI) improves the prognosis of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐ALL). However, the prognosis of cases of relapsed or refractory Ph‐ALL remains poor. Here, we aimed to assess the efficacy of T‐cell‐rich HLA‐haploidentical hematopoietic stem cell transplantation (TCR‐haplo‐HSCT) in eight patients with relapsed or refractory pediatric Ph‐ALL. Transplant‐related mortality was observed in two patients. All patients discontinued TKI after receiving TCR‐haplo‐HSCT. The 3‐year probability of overall survival and event‐free survival was 75.0 and 62.5%, respectively. These results indicate the efficacy of TCR‐haplo‐HSCT for relapsed/refractory pediatric Ph‐ALL. 相似文献
114.
Katsumi Hirose Takahiro Kato Takaomi Harada Tomoaki Motoyanagi Hiroki Tanaka Akihiko Takeuchi Ryohei Kato Shinya Komori Yuhei Yamazaki Kazuhiro Arai Noriyuki Kadoya Mariko Sato Yoshihiro Takai 《Journal of radiation research》2022,63(4):620
The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT. 相似文献
115.
Tsukasa Higuchi Kazuhiro Shimada Yoshiaki Cho Kisei Minami Kouichi Takeuchi Akiyuki Sakamoto 《Pediatrics international》2016,58(8):760-763
Although the effectiveness of subarachnoid continuous drug infusion has been established in cancer pain management, its clinical use in children is rare. A 14‐year‐old girl with neurofibromatosis type I complained of right leg pain stemming from a growing tumor on her right buttock. Continuous and breakthrough right leg pain were unbearable, even at high doses of systemic opioids that caused severe constipation and deep sedation. Subsequent continuous infusion of bupivacaine and morphine through a subarachnoid catheter effectively relieved the girl's pain. The corresponding decrease in systemic opioid also improved her activities of daily living. The patient eventually died of cachexia due to the rapidly growing buttock lesion that was pathologically confirmed post‐mortem as a malignant peripheral nerve sheath tumor. Subarachnoid continuous drug infusion may be very useful in controlling severe pain with few side‐effects, even in the field of pediatric palliative care. 相似文献
116.
Pin Xu Kazuhiro Shimomura Changhoon Lee Xiaofei Gao Eleanor H. Simpson Guocun Huang Chryshanthi M. Joseph Vivek Kumar Woo-Ping Ge Karen S. Pawlowski Mitchell D. Frye Saïd Kourrich Eric R. Kandel Joseph S. Takahashi 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(31)
117.
Kan Yonemori Yasutoshi Kuboki Kosei Hasegawa Takashi Iwata Hidenori Kato Kazuhiro Takehara Yasuyuki Hirashima Hisamori Kato Chaitali Passey Jeppe Klint Buchbjerg Jeffrey R. Harris Camilla
Mondrup Andreassen Leonardo Nicacio Ibrahima Soumaoro Keiichi Fujiwara 《Cancer science》2022,113(8):2788
New treatments, particularly second‐line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cytotoxic monomethyl auristatin E. This single‐arm, open‐label phase 1/2 trial evaluated the consistency of safety and efficacy outcomes of TV in Japanese patients with r/mCC to bridge the current findings with those reported in previous trials in non‐Japanese patients in the United States and Europe. In part 1 (dose escalation; N = 6), patients with advanced solid tumors received TV 1.5 or 2.0 mg/kg once every 3 weeks to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 (dose expansion; N = 17) evaluated the RP2D in r/mCC patients with 1–2 prior lines of therapy. In part 1, no dose‐limiting toxicities were observed, the MTD was not reached, and TV 2.0 mg/kg was established as the RP2D. In part 2, the most common treatment‐emergent adverse events were anemia (58.8%), nausea (58.8%), alopecia (47.1%), epistaxis (47.1%), and diarrhea (35.3%); adverse events of special interest were bleeding (76.5%), ocular events (35.3%), and peripheral neuropathy (17.6%), and were mostly grade 1/2. In part 2, confirmed objective response rate was 29.4%, median duration of response was 7.1 months, and median time to response was 1.2 months. In Japanese patients with r/mCC, TV demonstrated a manageable and tolerable safety, pharmacokinetics, and efficacy profile consistent with that observed in non‐Japanese patients. 相似文献
118.
Choi J Koh E Matsui F Sugimoto K Suzuki H Maeda Y Yoshida A Namiki M 《Fertility and sterility》2008,89(5):1177-1182
119.
Kim YG Sumiyoshi M Kawahira K Sakanaka M Kimura Y 《Phytotherapy research : PTR》2008,22(11):1423-1427
Red Ginseng (the roots of Panax ginseng C.A. Meyer) is used clinically in China, Korea and Japan for various diseases, including atherosclerosis, hypertension and stress etc. Although Red Ginseng roots have traditionally been thought to have antiageing effects, the basis for this hearsay is unclear. This study examined the effects of Red Ginseng extract on ultraviolet B (UVB)-irradiated skin ageing in mice. Oral administration of Red Ginseng extract (20 or 60 mg/kg, twice daily) prevented UVB-irradiated skin damage (increases of skin thickness and pigmentation, and reduction of skin elasticity). Furthermore, Red Ginseng extract inhibited the increases of epidermis and corium thickness induced by UVB irradiation. Red Ginseng extract inhibited the increase of skin TGF-beta1 content induced by UVB irradiation. These findings suggest that the protective action of Red Ginseng extract against UVB-irradiated skin ageing may be due partly to an inhibition of the increase of skin TGF-beta1 induced by UVB irradiation. In conclusion, the oral administration of Red Ginseng extract may be useful as a health supplement for protection against photoageing. 相似文献
120.
Miwa K Misumi K Shimada K Miyoshi N Inoue T Kawabe Y Moriyama K Ibara S Ikenoue T Sakamoto H 《Journal of perinatal medicine》2007,35(3):232-235
AIMS: A novel blood purification material that we previously reported as a superantigen- and cytokine-adsorbing device (SCAD) was evaluated for its ability to adsorb unbound, unconjugated bilirubin (UUBil) in vitro and in vivo. METHODS: In albumin-containing buffer, UUBil was dissolved and circulated through the SCAD column. Also, bilirubin was infused into low-body weight newborn piglets and hemoperfused for 3 h over SCAD columns. RESULTS: In albumin-containing buffer, concentration of bilirubin decreased from 34 to 0.6 mg/dL within 5 h and the SCAD fiber turned brown, indicating that bilirubin was adsorbed onto the surface of the adsorbent and was not degraded during the circulation. Using the hyperbilirubinemia swine, clearances of total bilirubin (TBil), direct bilirubin (DBil), and indirect bilirubin (IdBil) were significantly higher (P<0.01) in the SCAD group compared with the control group. The clearances of TBil, DBil, and IdBil at 3 h after the initiation of the bilirubin infusion were 0.47, 0.53, and 0.45 mL/min, respectively, at a blood flow rate of 2.5 mL/min, and this result indicates that almost 20% of bilirubins were adsorbed to the SCAD column in a single passage. CONCLUSION: These results provide initial evidence that SCAD treatment is effective in the removal of UUBil and can be performed safely in newborn animals. 相似文献